Understanding long-term survival in NSCLC immunotherapy
Part of Cancer, Lungs & breathing clinical trials.
This study looks at patients with advanced non-small cell lung cancer who received immunotherapy (immune checkpoint inhibitors) alone or in combination with other treatments. It aims to understand why some patients survive longer than others by analyzing their medical data and using AI to predict outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced or locally advanced non-small cell lung cancer (NSCLC).
- You received immunotherapy (immune checkpoint inhibitor) as your first or later treatment, either alone or with other therapies.
- Your medical records come from one of the participating cancer hospitals or from a completed phase III clinical trial (like Choice-01, Rationale-307, or Rationale-304).
- Your doctors have your complete medical information and follow-up data.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunotherapy again can help people with advanced non-small cell lung cancer whose disease stayed stable for at least 2 years on their first immunotherapy but then started growing. It aims to see if a second course of treatment can work again.
This study looks at the genetic makeup of lung cancer tumors after patients receive immunotherapy before surgery. It aims to understand why some tumors do not completely disappear and may help guide future treatments.
This study reviews medical records from people with advanced lung cancer who have already tried immunotherapy and their cancer got worse. The goal is to compare different second-line treatments to see which might work better after immunotherapy stops working.
This study looks at how well immunotherapy given before surgery works for non-small cell lung cancer. It aims to help doctors understand real-world outcomes for patients who receive this treatment.
This study is looking at biomarkers (clues in your blood and tumor) to better understand how advanced lung cancer responds to immunotherapy. It aims to help doctors predict which treatments might work best for you in the future.
This study looks at genetic material from tumor samples to find patterns that can predict whether immunotherapy will work for people with advanced non-small cell lung cancer (NSCLC). The goal is to improve how doctors choose treatments for each patient.
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.